Fig. 4From: Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studiesCNS-PFS of patients with and without additional plasma gene alterations at baseline. A All doses of furmonertinib; B Eighty mg orally once daily of furmonertinib. Plasma gene alterations in addition to EGFR mutations including tumor suppressor gene (PTEN, TP53, or RB1) mutations and oncogenic driver gene (ALK, BRAF, ERBB2, KRAS, MET, RET, ROS1, or amplificated EGFR) alterations. CNS, central nervous system. PFS, progression-free survival. CI, confidence interval. NR, not reached. NA, not available. HR, hazard ratio Back to article page